William Garner - Kintara Therapeutics Director
Director
Dr. Bill Garner, M.D., MPH., is appointed as the Director of DelMar Pharmaceuticals, Inc. Dr. Garner is one of the founders and has served as a director of DelMar since inception and is currently CEO of Invion Ltd. . Dr. Garner is an experienced entrepreneur and investor and is a threetime Kauffman Finalist. He served as President and Chief Executive Officer of Urigen Pharmaceuticals, Inc. from December 2005 to December 2010 where he moved a procedurebased drug from a university license to a phase II multicenter clinical trial which achieved statistical significance on all end points in Painful Bladder SyndromeInterstitial Cystitis. He is founder and managing director of EGB Advisors, LLC, a pharmaceutical commercialization boutique. Through this entity, Dr. Garner has worked on a number of pharmaceutical business transactions and has raised financing for both Urigen Pharmaceuticals, Inc. and another company that he founded, Inverseon, Inc., which is developing a novel therapy for smoking cessation, asthma and other pulmonary diseases. Before this, Dr. Garner worked in medical affairs at Hoffmann LaRoche in oncology. Prior to Roche, Dr. Garner was in the VC department at Paramount Capital Investments in New York City. He serves on the boards of ImmunoGenetix in Kansas City and Angel Investor Card in San Francisco. Dr. Garner has a Master of Public Health from Harvard and received his M.D. degree from New York Medical College. Dr. Garner did residency training in Anatomic Pathology at ColumbiaPresbyterian and is currently a licensed physician in the State of New York. since 2013.
Age | 48 |
Tenure | 11 years |
Phone | 858-350-4364 |
Web | http://www.delmarpharma.com |
Kintara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (136.86) % which means that it has lost $136.86 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (316.72) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Mark Zandi | MGIC Investment Corp | 61 | |
Melissa Lora | MGIC Investment Corp | 58 | |
Chuck Chaplin | MGIC Investment Corp | 63 | |
Barbara Higgins | Employers Holdings | 53 | |
Robert Brown | BCE Inc | 74 | |
Jennifer Tory | BCE Inc | 65 | |
Jingsong Qian | Kandi Technologies Group | 53 | |
Thomas Richards | BCE Inc | 65 | |
Sophie Brochu | BCE Inc | 55 | |
Robert Simmonds | BCE Inc | 67 | |
Ronald Mosher | Employers Holdings | 72 | |
Valerie Glenn | Employers Holdings | 65 | |
Carole Taylor | BCE Inc | 68 | |
Steven Pfeiffer | Iridium Communications | 71 | |
Paul Weiss | BCE Inc | 71 | |
Monique Leroux | BCE Inc | 67 | |
Yi Lin | Kandi Technologies Group | 63 | |
Alvin Krongard | Iridium Communications | 81 | |
Parker Rush | Iridium Communications | 58 | |
Gary Poliner | MGIC Investment Corp | 67 | |
Timothy Holt | MGIC Investment Corp | 67 |
Management Performance
Return On Equity | -316.72 | |||
Return On Asset | -136.86 |
Kintara Therapeutics Leadership Team
Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Scott Praill, CFO and Principal Accounting Officer | ||
John Bell, Independent Director | ||
William Garner, Director | ||
Erich Mohr, Independent Director | ||
Saiid Zarrabian, Director | ||
Robert Toth, Director | ||
Dennis Brown, Chief Scientific Officer, Director | ||
Jeffrey Bacha, President CEO, Director | ||
Lynda Cranston, Independent Director | ||
Robert Hoffman, Independent Director | ||
Napoleone Ferrara, Director |
Kintara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -316.72 | |||
Return On Asset | -136.86 | |||
Current Valuation | 13.09 M | |||
Shares Outstanding | 11.46 M | |||
Shares Owned By Insiders | 1.44 % | |||
Shares Owned By Institutions | 12.46 % | |||
Number Of Shares Shorted | 246.63 K | |||
Price To Earning | (1.68) X | |||
Price To Book | 3.26 X | |||
EBITDA | (8.26 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kintara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kintara Therapeutics' short interest history, or implied volatility extrapolated from Kintara Therapeutics options trading.
Pair Trading with Kintara Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Global Correlations Find global opportunities by holding instruments from different markets |